Eyenovia, Inc. (EYEN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN). The investigation concerns whether Eyenovia and certain of its officers and/or directors have violated federal securities laws and breached fiduciary duties.
On October 25, 2021, Eyenovia issued a press release “announc[ing] that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product by the U.S. Food and Drug Administration (FDA) in a Complete Response Letter (CRL) for the company’s new drug application (NDA) received on October 22, 2021.” On this news, Eyenovia’s stock price fell sharply during intraday trading on October 25, 2021.
If you are aware of any facts relating to this investigation, or purchased Eyenovia shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.